ADC Therapeutics(ADCT) Newsfilter·2024-05-09 11:15Company Overview - ADC Therapeutics is a commercial-stage global leader in antibody drug conjugates (ADCs) [2] - The company is focused on transforming treatment for patients with hematologic malignancies and solid tumors [2] Product Development - ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [2] - ZYNLONTA is also being developed in combination with other agents and in earlier lines of therapy [2] - The company has multiple ADCs in ongoing clinical and preclinical development [2] Upcoming Events - Ameet Mallik, CEO of ADC Therapeutics, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on May 14, 2024, at 1:35 p.m. ET [1] - A live webcast of the presentation will be available on the company's website, with a replay accessible for approximately 30 days [1]